<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04688008</url>
  </required_header>
  <id_info>
    <org_study_id>SHR8735-112</org_study_id>
    <nct_id>NCT04688008</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability of Early Phase and Late Phase Hetrombopag Olamine Formulations</brief_title>
  <official_title>An Open-label, Randomized, Single-dose, Two -Period, Crossover Study to Investigate the Relative Bioavailability of Early Phase and Late Phase Hetrombopag Olamine Formulations in Healthy Chinese Adult Subjects Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the relative bioavailability of early phase&#xD;
      and late phase hetrombopag olamine formulations in healthy Chinese adult subjects under&#xD;
      fasting conditions. The secondary objective of the study is to evaluate the safety of&#xD;
      hetrombopag olamine in healthy Chinese adult subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 18, 2020</start_date>
  <completion_date type="Actual">October 30, 2020</completion_date>
  <primary_completion_date type="Actual">October 12, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak plasma concentration (Cmax)</measure>
    <time_frame>0-120 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the plasma concentration vs time curve (AUC0-120).</measure>
    <time_frame>0-120 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the blood concentration vs time curve (AUC0-inf).</measure>
    <time_frame>0-infinity</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Drug Concentration in Plasma After Single Dose (Tmax)</measure>
    <time_frame>0-120 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life Associated With the Terminal Slope (tÂ½)</measure>
    <time_frame>0-120 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Bioavailability Study</condition>
  <arm_group>
    <arm_group_label>Treatment sequence #1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>29 of 58 subjects were given single oral dose of early phase hetrombopag olamine formulation in period 1 and late phase formulation in period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence #2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>29 of 58 subjects were given single oral dose of late phase hetrombopag olamine formulation in period 1 and early phase formulation in period 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hetrombopag</intervention_name>
    <description>Drug: Early phase hetrombopag olamine formulation single oral dose of 5 mg hetrombopag under fasting conditions&#xD;
Drug: Late phase hetrombopag olamine formulation single oral dose of 5 mg hetrombopag under fasting conditions</description>
    <arm_group_label>Treatment sequence #1</arm_group_label>
    <arm_group_label>Treatment sequence #2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Sign the informed consent before the trial, and fully understand the trial content,&#xD;
             process and possible adverse reactions;&#xD;
&#xD;
          2. Ability to complete the study as required by the protocol;&#xD;
&#xD;
          3. Healthy male or female subjects aged 18 to 45 (including 18 and 45) at the date of&#xD;
             signing the informed consent;&#xD;
&#xD;
          4. Body mass index (BMI) within the range of 19 ~ 26 kg /m2 (including 19 and 26);&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergic constitution;&#xD;
&#xD;
          2. History of drug use, or drug abuse screening positive;&#xD;
&#xD;
          3. Alcoholic or often drinkers;&#xD;
&#xD;
          4. History of deep vein thrombosis, or any other thromboembolic event;&#xD;
&#xD;
          5. A clear medical history of important primary organ diseases such as nervous system,&#xD;
             cardiovascular system, urinary system, digestive system, respiratory system,&#xD;
             metabolism and musculoskeletal system.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Second Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 11, 2020</study_first_submitted>
  <study_first_submitted_qc>December 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

